{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T04:17:10Z","timestamp":1783743430482,"version":"3.55.0"},"reference-count":28,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2008,3,25]],"date-time":"2008-03-25T00:00:00Z","timestamp":1206403200000},"content-version":"vor","delay-in-days":2975,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Australian and New Zealand Journal of Medicine"],"published-print":{"date-parts":[[2000,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p> <jats:italic>Aim<\/jats:italic>: To compare the clinical and immunological efficacy, and tolerance of two dosage regimens of zidovudine (ZDV) in an adult Thai population with early symptomatic human immunodeficiency virus (HIV) disease and to identify important clinical issues associated with conducting HIV trials in South\u2010East Asia.<\/jats:p><jats:p> <jats:italic>Methods:<\/jats:italic> HIV\u2010infected Thai adults, with early symptomatic HIV disease and CD4 lymphocyte counts less than 400\/mm3, who were managed in the infectious diseases clinics at two university teaching hospitals in Bangkok, Thailand, were enrolled in a randomised, open\u2010label, dose\u2010regimen comparison trial of ZDV. Two oral ZDV dosing regimens: regimen A, 100 mg tid+200 mg nocte (ZDV\u2010A) vs regimen B, 250 mg bid (ZDV\u2010B) were compared. The main outcome measures were:<\/jats:p><jats:p>1. Clinical efficacy: rate of progression to acquired immunodeficiency syndrome (AIDS) or death.<\/jats:p><jats:p>2. Immunologic efficacy: changes in CD4 lymphocyte numbers compared to baseline; rate of decline of CD4 lymphocyte numbers to less than 100\/mm3.<\/jats:p><jats:p>3. Toxicity, as defined by clinical symptomatology and laboratory parameters.<\/jats:p><jats:p> <jats:italic>Results:<\/jats:italic> Two hundred and four patients were enrolled (103 ZDV\u2010A; 101 ZDV\u2010B) of whom 195 were followed beyond baseline. Patients were typical of those encountered with HIV in Thailand: mean age 33 years; 89% male; 88% heterosexual HIV acquisition; mean baseline CD4 lymphocyte count 241\/mm3. Follow\u2010up while on therapy was comparable for the two groups (mean +SD): 533+236 days (ZDV\u2010A) vs 5925210 days (ZDV\u2010B). One hundred and eleven patients (57%; 51 ZDV\u2010A, 60 ZDV\u2010B) were treated for at least 22 months (669530 days). Clinical and immunological outcomes for ZDV\u2010A and ZDV\u2010B, including rate of progression to AIDS or death, development of non\u2010AIDS\u2010defining opportunistic infections, mean changes in CD4 lymphocyte numbers\/mm3, difference in area under the CD4:time distribution curve and difference in the rate of decline of CD4 lymphocyte numbers to less than 100\/mm3, were not significantly different. The presence of oral hairy leukoplakia or unintential weight loss of 10\u201320% at enrolment were significantly associated with the later development of AIDS (p=0.03 and 0.04, respectively). ZDV\u2010associated toxicity was similar for both regimens. Maintaining protocol adherence and appropriate clinical follow\u2010up emerged as important practical issues.<\/jats:p><jats:p> <jats:italic>Conclusion:<\/jats:italic> In Thai adults, ZDV 100 mg tid+200 mg nocte and ZDV 250 mg bid have similar clinical and immunological efficacy. Rates of ZDV toxicity are comparable to those reported in non\u2010Asian populations. Despite limitations in medical care access and maintaining long\u2010term follow\u2010up, successful trials of antiretroviral agents are feasible in South\u2010East Asia and multi\u2010drug treatment trials should be pursued in appropriate institutions.<\/jats:p>","DOI":"10.1111\/j.1445-5994.2000.tb01048.x","type":"journal-article","created":{"date-parts":[[2008,3,25]],"date-time":"2008-03-25T09:31:26Z","timestamp":1206437486000},"page":"11-20","source":"Crossref","is-referenced-by-count":8,"title":["A comparison of two dosing regimens of zidovudine in Thai adults with early symptomatic HIV infection. Conducting clinical HIV trials in South\u2010East Asia"],"prefix":"10.1111","volume":"30","author":[{"given":"P.","family":"Phanuphak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. L.","family":"Grayson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Sirivichayakul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Suwanagool","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Ruxrungtham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Hanvanich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Ratanasuwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Ubolyam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. D.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. A.","family":"Wanke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. M.","family":"Hammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,3,25]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199608013350501"},{"issue":"2","key":"e_1_2_1_3_2","first-page":"131","article-title":"The recent epidemiology of HIV and AIDS in Thailand","volume":"8","author":"Brown T","year":"1994","journal-title":"AIDS"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199404000-00018"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.84.12.2026"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199004053221401"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-112-10-727"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199010113231501"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(88)90283-8"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.2502840"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/12.Supplement_5.S570"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199610103351501"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199610103351502"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)05387-1"},{"key":"e_1_2_1_15_2","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1001\/jama.1996.03540020068031","article-title":"Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel","volume":"276","author":"Carpenter CCJ","year":"1996","journal-title":"JAMA"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199709113371101"},{"issue":"1","key":"e_1_2_1_17_2","first-page":"3","article-title":"Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome","volume":"36","author":"CDC","year":"1987","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"e_1_2_1_18_2","volume-title":"Division of AIDS table for grading severity of adult adverse experiences","year":"1996"},{"key":"e_1_2_1_19_2","first-page":"114","article-title":"CD4 percentage, CD4 number, and CD4:CD8 ratio in HIV infection: Which to choose and how to use","volume":"2","author":"Taylor JMG","year":"1989","journal-title":"J AIDS"},{"key":"e_1_2_1_20_2","first-page":"770","article-title":"Predictive value of CD4 lymphocyte numbers for the development of opportunistic infections and malignancies in HIV\u2010infected persons","volume":"4","author":"Crowe SM","year":"1991","journal-title":"J AIDS"},{"key":"e_1_2_1_21_2","first-page":"1217","volume-title":"Principles and practice of infectious diseases","author":"Chaisson RE","year":"1995"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198810273191704"},{"issue":"1","key":"e_1_2_1_23_2","first-page":"103","article-title":"Natural history and clinical presentation of HIV\u20101 infection in adults","volume":"5","author":"Colebunders RL","year":"1991","journal-title":"AIDS"},{"issue":"1","key":"e_1_2_1_24_2","first-page":"143","article-title":"The pathology of severe morbidity and mortality caused by HIV infection in Africa","volume":"5","author":"Lucas SB","year":"1991","journal-title":"AIDS"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)90006-X"},{"key":"e_1_2_1_26_2","unstructured":"KroonE UngsedhaphanC RuxrungthamKet al.Study HIV\u2010NAT 001: a randomized double\u2010blind comparative trial to evaluate the efficacy of combination antiviral therapy with ZDV 200 mg TID plus ddC 0.75 mg TID versus ZDV 100 mg TID plus ddC 0.375 mg TID for the treatment of HIV\u20101 infection in a Thai study population. 5th Conference on Retroviruses and Opportunistic Infections [Abstr. 665] Chicago February 1998."},{"key":"e_1_2_1_27_2","unstructured":"RuxrungthamK KroonE UngsedhaphanCet al.Study HIV\u2010NAT 002: the safety and efficacy of didanosine (ddI)\u00b1stavudine (d4T): high\/low dose combinations in a high prevalence HIV\u20101 Clade E antiretroviral naive Thai adults with CD4 counts 150\u2013350 mm3. 5th Conference on Retroviruses and Opportunistic Infections [Abstr. 666]. Chicago February 1998."},{"key":"e_1_2_1_28_2","first-page":"163","article-title":"Clinical trials in Asia","volume":"12","author":"Phanuphak P","year":"1998","journal-title":"AIDS"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.280.1.78"}],"container-title":["Australian and New Zealand Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1445-5994.2000.tb01048.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1445-5994.2000.tb01048.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,29]],"date-time":"2023-10-29T10:32:31Z","timestamp":1698575551000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1445-5994.2000.tb01048.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,2]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2000,2]]}},"alternative-id":["10.1111\/j.1445-5994.2000.tb01048.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1445-5994.2000.tb01048.x","archive":["Portico"],"relation":{},"ISSN":["0004-8291"],"issn-type":[{"value":"0004-8291","type":"print"}],"subject":[],"published":{"date-parts":[[2000,2]]}}}